在聚乙二醇化干扰素α和利巴韦林治疗慢性丙型肝炎病毒感染期间发生1型糖尿病。
Onset of Type 1 Diabetes Mellitus During Pegylated-interferon Alfa and Ribavirin Therapy for Chronic Hepatitis C Virus Infection.
作者信息
Ranganathan Raghini, Janarthanan Krishnaveni, Rajasekaran Senthilkumar
机构信息
Department of Gastroenterology, PSG Institute of Medical Sciences and Research, Coimbatore - 641004, Tamil Nadu, India.
出版信息
J Clin Exp Hepatol. 2012 Mar;2(1):86-7. doi: 10.1016/S0973-6883(12)60089-9. Epub 2012 Apr 12.
Abstract
A 16-year-old female was treated with pegylated-interferon (PEG-IFN) alfa (a)-2b and ribavirin combination therapy for chronic hepatitis C virus (HCV) infection. She attained rapid virological response. She presented with diabetic ketoacidosis after 41 weeks of therapy. Anti-glutamic acid decarboxylase antibodies and islet cell antibodies were negative. Her fasting serum C-peptide level was <0.1 ng/mL, and the treatment course was completed. This case underlines the importance of periodic plasma glucose monitoring in patients during and after PEG-IFN and ribavirin therapy.
摘要
一名16岁女性接受聚乙二醇化干扰素（PEG-IFN）α-2b和利巴韦林联合治疗慢性丙型肝炎病毒（HCV）感染。她获得了快速病毒学应答。在治疗41周后，她出现了糖尿病酮症酸中毒。抗谷氨酸脱羧酶抗体和胰岛细胞抗体均为阴性。她的空腹血清C肽水平<0.1 ng/mL，治疗疗程完成。该病例强调了在接受PEG-IFN和利巴韦林治疗期间及之后对患者进行定期血糖监测的重要性。
相似文献
1
Onset of Type 1 Diabetes Mellitus During Pegylated-interferon Alfa and Ribavirin Therapy for Chronic Hepatitis C Virus Infection.在聚乙二醇化干扰素α和利巴韦林治疗慢性丙型肝炎病毒感染期间发生1型糖尿病。
J Clin Exp Hepatol. 2012 Mar;2(1):86-7. doi: 10.1016/S0973-6883(12)60089-9. Epub 2012 Apr 12.
2
3
Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin-A Multicenter Study.印度丙型肝炎病毒所致慢性肝炎（CH-C）的治疗：一项比较每日干扰素-α-2b与利巴韦林联用和每日干扰素-α-2b与甘草酸联用的随机对照多中心研究。
J Clin Exp Hepatol. 2012 Mar;2(1):10-8. doi: 10.1016/S0973-6883(12)60079-6. Epub 2012 Apr 12.
4
Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.比较聚乙二醇化干扰素α-2b与聚乙二醇化干扰素α-2a加利巴韦林治疗人类免疫缺陷病毒患者慢性丙型肝炎的随机试验。
Hepatology. 2009 Jan;49(1):22-31. doi: 10.1002/hep.22598.
5
Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.个体化给药疗效与固定剂量给药对比以评估聚乙二醇化干扰素最佳治疗方案（IDEAL）试验的科学依据和研究设计：确定基因1型慢性丙型肝炎患者的最佳给药剂量
J Viral Hepat. 2008 Jul;15(7):475-81. doi: 10.1111/j.1365-2893.2008.00973.x. Epub 2008 Mar 24.
6
Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.聚乙二醇化α-干扰素-2a联合利巴韦林与聚乙二醇化α-干扰素-2b联合利巴韦林用于慢性丙型肝炎病毒的初始治疗：前瞻性、非随机研究。
J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.
7
High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection.聚乙二醇化干扰素α治疗慢性丙型肝炎病毒感染期间或治疗后不久，1型糖尿病发病率较高。
Liver Int. 2008 Jan;28(1):39-46. doi: 10.1111/j.1478-3231.2007.01610.x. Epub 2007 Nov 21.
8
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.甲硫米泊苷、聚乙二醇干扰素和利巴韦林用于1型慢性丙型肝炎中对聚乙二醇干扰素和利巴韦林无反应者的治疗。
Hepatology. 2009 Dec;50(6):1719-26. doi: 10.1002/hep.23204.
9
PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.聚乙二醇化干扰素α-2b与利巴韦林联合治疗丙型肝炎病毒相关性系统性血管炎患者。
Arthritis Rheum. 2005 Mar;52(3):911-5. doi: 10.1002/art.20958.
10
A case of type 1 diabetes onset and recurrence of Graves' disease during pegylated interferon-α plus ribavirin treatment for chronic hepatitis C.1例慢性丙型肝炎患者在聚乙二醇化干扰素-α联合利巴韦林治疗期间发生1型糖尿病并复发格雷夫斯病。
Intern Med. 2010;49(18):1987-90. doi: 10.2169/internalmedicine.49.3831. Epub 2010 Sep 15.
引用本文的文献
1
Association between hepatitis C antiviral treatment and diabetes mellitus: A case series.丙型肝炎抗病毒治疗与糖尿病之间的关联：病例系列研究
J Assoc Med Microbiol Infect Dis Can. 2020 Jun 23;5(2):104-110. doi: 10.3138/jammi-2019-0007. eCollection 2020 Jun.
本文引用的文献
1
Type 1 diabetes and interferon therapy: a nationwide survey in Japan.1 型糖尿病与干扰素治疗：日本全国性调查。
Diabetes Care. 2011 Sep;34(9):2084-9. doi: 10.2337/dc10-2274. Epub 2011 Jul 20.
2
High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection.聚乙二醇化干扰素α治疗慢性丙型肝炎病毒感染期间或治疗后不久，1型糖尿病发病率较高。
Liver Int. 2008 Jan;28(1):39-46. doi: 10.1111/j.1478-3231.2007.01610.x. Epub 2007 Nov 21.
3
Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.持续病毒学应答与慢性丙型肝炎病毒感染患者血糖异常发生率的降低相关。
Diabetes Care. 2006 Nov;29(11):2462-6. doi: 10.2337/dc06-0456.
4
Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus.聚乙二醇干扰素在一名复发性丙型肝炎病毒感染的肝移植患者中诱发自身免疫性肝炎
Transplantation. 2006 Feb 15;81(3):488-90. doi: 10.1097/01.tp.0000196716.07188.c4.
5
Autoantibodies in diabetes.糖尿病中的自身抗体
Diabetes. 2005 Dec;54 Suppl 2:S52-61. doi: 10.2337/diabetes.54.suppl_2.s52.
6
Potential mechanisms of interferon-alpha induced autoimmunity.干扰素-α诱导自身免疫的潜在机制。
Autoimmunity. 2003 Dec;36(8):519-23. doi: 10.1080/08916930310001602137.
7
Mechanisms of action of interferon and nucleoside analogues.干扰素和核苷类似物的作用机制。
J Hepatol. 2003;39 Suppl 1:S93-8. doi: 10.1016/s0168-8278(03)00207-1.
8
Systemic lupus erythematosus after alpha-interferon therapy for chronic hepatitis C: a case report and review of the literature.α干扰素治疗慢性丙型肝炎后发生系统性红斑狼疮：一例报告及文献复习
Am J Gastroenterol. 2000 Jan;95(1):310-2. doi: 10.1111/j.1572-0241.2000.01715.x.
9
Acute autoimmune hemolytic anemia during interferon-alpha therapy for chronic hepatitis C.慢性丙型肝炎干扰素-α治疗期间的急性自身免疫性溶血性贫血
Dig Dis Sci. 1999 Jul;44(7):1366-7. doi: 10.1023/a:1026643500569.
10
New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine.干扰素α作用机制的新见解：一种免疫调节和抗炎细胞因子。
Gastroenterology. 1997 Mar;112(3):1017-21. doi: 10.1053/gast.1997.v112.pm9041265.
Zotero 插件